Phaseline

Targets › NONE

NONE: drug programs, companies and trials

4 programs from 4 companies in 4 trials: 2 Phase 2, 1 Phase 4, 1 Phase 3; Oncology, Infectious disease, Immunology; next expected readout Mar 2027.

Open in Phaseline: the race on NONE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
New York Medical CollegeMetronidazole Vaginal
Nitroimidazole antimicrobial that generates reactive intermediates to disrupt bacterial an
NONEPhase 4Post-Op Infection–
Fudan UniversityCarboplatin
DNA-damaging alkylating agent; platinum-based chemotherapy
NONEPhase 3Triple-negative Breast CancerMar 2027
Peter BlackST-02
mucoadhesive gemcitabine suspension for pyelocaliceal instillation; nucleoside analog inhi
NONEPhase 2Urothelial Carcinoma of the Renal Pelvis and UreterApr 2028
Citryll[89Zr]Zr-CIT
Radiolabeled monoclonal antibody imaging agent targeting neutrophil extracellular traps (N
NONEPhase 2RA–

Conditions

Post-Op Infection (1) Urothelial Carcinoma of the Renal Pelvis and Ureter (1) Triple-negative Breast Cancer (1) RA (1)

Modalities

small molecule (4)

Companies

New York Medical College (1) Peter Black (1) Fudan University (1) Citryll (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.